

Confidentiality Agreement Regarding SITC's Cancer Immunotherapy Clinical Practice Guideline Draft

I understand that the information within the Cancer Immunotherapy Clinical Practice Guideline (CPG) draft that I am requesting is highly confidential and contains information that has not yet been made available to the general public. Furthermore, I understand that while this information is being made available to me prior to public release, it is for the sole purpose of expert review and comment on the Cancer Immunotherapy CPG draft.

As a requirement to being allowed access to SITC's Cancer Immunotherapy CPG draft prior to public release, I hereby agree that until the Cancer Immunotherapy CPG has been made public by SITC, I will regard each Cancer Immunotherapy CPG draft and the associated information contained within as confidential.

With specific regard, and without limiting the generality of my agreement to maintain confidentiality of the draft, I understand that:

- During the term of this Agreement and thereafter, I will not directly or indirectly publish any information included within a Cancer Immunotherapy CPG draft(s), nor disseminate or otherwise disclose, deliver or make available the information to any third party for publication, any time before the Cancer Immunotherapy CPG is made available to the public.
- I will not use – nor provide the information to another who may use – the information included in the Cancer Immunotherapy CPG draft to trade in the securities of any issuer. Violation of this component of the agreement constitute a violation of federal or state securities laws and may subject me to civil or criminal liability.
- SITC does not guarantee – direct or implied – as to the accuracy or comprehensiveness of the Cancer Immunotherapy CPG draft. SITC, its directors, members, and representatives do not hold any liability resulting from the information contained within or the use of the Cancer Immunotherapy CPG draft.
- All comments received during the open comment period will be reviewed by the Guideline Expert Panel leadership. Comments are advisory only and SITC is not obligated to make any suggested changes based on comments received. SITC will consider all submissions, but will not respond directly to individual commenters.

To obtain access to SITC's **"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events,"** I hereby agree to the terms of this Confidentiality Agreement.

*If you are signing this NDA and are doing so not as the sole person providing comment, but on behalf of a team or group within your corporation or organization, you accept full responsibility for the terms above and you are required to list the team or group's name below

NAME (Printed): _____

COMPANY/INSITUATION: _____

*ON BEHALF OF: _____

SIGNATURE: _____ DATE: _____

Please email completed form to scientificresources@sitcancer.org.

*Once received, a copy of the guideline will be emailed to you within 1-2 business days for your review.
All comments must be received by Monday, February 8, 2021.*